Edition:
United States

Zhejiang Hisun Pharmaceutical Co Ltd (600267.SS)

600267.SS on Shanghai Stock Exchange

16.17CNY
--
Change (% chg)

-- (--)
Prev Close
¥16.17
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,459,901
52-wk High
¥16.70
52-wk Low
¥10.24

Latest Key Developments (Source: Significant Developments)

Zhejiang Hisun Pharmaceutical passes FDA approval
Tuesday, 21 Nov 2017 05:43am EST 

Nov 21(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it received approval for a kind of tablet from U.S Food and Drug Administration .  Full Article

Zhejiang Hisun Pharmaceutical unit says product gets FDA approval
Monday, 20 Nov 2017 05:04am EST 

Nov 20(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says co's Hangzhou-based unit's product simvastatin tablets, gets approval from U.S. Food and Drug Administration.  Full Article

Zhejiang Hisun Pharmaceutical says product gets FDA approval
Thursday, 16 Nov 2017 02:35am EST 

Nov 16 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::Says its product, mycophenolate mofetil capsules, gets approval from U.S. Food and Drug Administration .  Full Article

Zhejiang Hisun Pharmaceutical says change of CFO
Tuesday, 17 Oct 2017 10:58pm EDT 

Oct 18 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::Says it appoints Liu Yuanyan as new CFO, replacing Guan Xuhua who resigns from the position due to internal change in job role.  Full Article

Zhejiang Hisun Pharmaceutical receives TGA-GMP certificate
Wednesday, 11 Oct 2017 04:20am EDT 

Oct 11 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it received goods manufacture practice (GMP) certificate from Therapeutic Goods Administration .Certificate issued to crude drugs manufactured by the company and the valid period is until Nov. 26, 2020 .  Full Article

Zhejiang Hisun Pharmaceutical sub-subsidiary passes FDA approval
Monday, 11 Sep 2017 10:30am EDT 

Sept 11(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says its Zhejiang-based sub-subsidiary received FDA approval for metformin sustained release tablet from U.S Food and Drug Administration .* Company will be able to sell its metformin sustained release tablet in the United States after receiving the FDA approval.  Full Article

Zhejiang Hisun Pharmaceutical to set up pharmaceutical unit in Zhejiang
Thursday, 10 Aug 2017 11:17pm EDT 

Aug 11(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>:Says it plans to set up a wholly owned pharmaceutical unit in Zhejiang, with registered capital of 10 million yuan .  Full Article

Zhejiang Hisun Pharmaceutical to pay FY 2016 annual div on July 7
Friday, 30 Jun 2017 03:09am EDT 

June 30(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says it will pay FY 2016 dividend to shareholders of record on July 6.* The company's shares will be traded ex-right and ex-dividend on July 7 and the dividend will be paid on July 7.  Full Article

Zhejiang Hisun Pharmaceutical receives GMP certificate
Wednesday, 28 Jun 2017 02:24am EDT 

June 28(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says it received goods manufacture practice (GMP) certificate from Zhejiang Food and Drug Administration.* Says certificate issued to mycophenolate mofetil manufactured by the company and the valid period is until June 25, 2022.  Full Article

Zhejiang Hisun Pharmaceutical receives administrative order
Tuesday, 25 Apr 2017 05:10am EDT 

April 25(Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS> ::* Says it received an administrative order from Zhejiang Regulatory Bureau of China Securities Regulatory Commission, regarding information disclosure and false financial report .  Full Article

BRIEF-Zhejiang Hisun Pharmaceutical passes FDA approval

* Says it received approval for a kind of tablet from U.S Food and Drug Administration